Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prothena Corp (NQ: PRTA )

52.50 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 52.50
Bid (Size) 48.69 (1)
Ask (Size) 52.50 (3)
Prev. Close 52.50
Today's Range 52.50 - 52.50
52wk Range 28.99 - 79.65
Shares Outstanding 45,047,449
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Prothena to Participate in Upcoming Healthcare Conferences
From Prothena Corporation plc
Via Business Wire
Expert Ratings for Prothena Corp
Via Benzinga

Performance

YTD
-1.87%
-1.87%
1 Month
-8.17%
-8.17%
3 Month
-24.79%
-24.79%
6 Month
+11.77%
+11.77%
1 Year
+71.51%
+71.51%

More News

Read More
JMP Securities Maintains Outperform Rating for Prothena Corp: Here's What You Need To Know
Via Benzinga
Prothena Reports Second Quarter 2023 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Earnings Scheduled For August 3, 2023
Via Benzinga
Prothena Corp's Earnings Outlook
Via Benzinga
Expert Ratings for Prothena Corp
Via Benzinga
8 Analysts Have This to Say About Prothena Corp
Via Benzinga
Looking Into Prothena Corp's Return On Capital Employed
Via Benzinga
Prothena to Report Second Quarter 2023 Financial Results on August 3
From Prothena Corporation plc
Via Business Wire
Prothena Presents New Research in the Treatment of Alzheimer’s Disease at Alzheimer’s Association International Conference® 2023 (AAIC®)
From Prothena Corporation plc
Via Business Wire
Prothena to Present New Data from Alzheimer’s Disease Programs at Alzheimer’s Association International Conference® 2023 (AAIC®)
From Prothena Corporation plc
Via Business Wire
Recap: Prothena Corp Q1 Earnings
Via Benzinga
Prothena Corp Earnings Preview
Via Benzinga
Where Prothena Corp Stands With Analysts
Via Benzinga
Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody
From Prothena Corporation plc
Via Business Wire
Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab
From Prothena Corporation plc
Via Business Wire
Prothena to Participate in Jefferies 2023 Healthcare Conference
From Prothena Corporation plc
Via Business Wire
Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors
From Prothena Corporation plc
Via Business Wire
Prothena Reports First Quarter 2023 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Another Sucess In Alzheimer’s Disease
Via Talk Markets
Prothena to Report First Quarter 2023 Financial Results on May 4
From Prothena Corporation plc
Via Business Wire
Prothena to Participate in 2023 Bank of America Healthcare Conference
From Prothena Corporation plc
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.